Targeting Histone Demethylase GASC1/JMJD2C/KDM4C as a Novel Therapeutic Strategy in Castration-Resistant Prostate Cancer PRINCIPAL INVESTIGATOR:
نویسنده
چکیده
s: 1. Zhang L, Hou JL, Holowatyj A and Yang Z-Q. The role of histone demethylase GASC1 in promoting prostate cancer progression. 104st American Association for Cancer Research Annual Meeting in Washington, DC, Apr 4-10, 2013 (see Appendix) 2. Yang Z-Q. The role of histone demethylase GASC1 in cancer and its therapeutic potential. COLD SPRING HARBOR ASIA: DifferentiationTherapy and Advances in Cancer, Suzhou, China. October 20-24, 2012 (Selected for the oral presentation)
منابع مشابه
Histone demethylase JMJD2C: epigenetic regulators in tumors
Histone methylation is one of the major epigenetic modifications, and various histone methylases and demethylases participate in the epigenetic regulating. JMJD2C has been recently identified as one of the histone lysine demethylases. As one member of the Jumonji-C histone demethylase family, JMJD2C has the ability to demethylate tri- or di-methylated histone 3 and 2 in either K9 (lysine residu...
متن کاملRegulation of adipogenesis by nuclear receptor PPARγ is modulated by the histone demethylase JMJD2C
A potential strategy to combat obesity and its associated complications involves modifying gene expression in adipose cells to reduce lipid accumulation. The nuclear receptor Peroxisome Proliferator-activated receptor gamma (PPARγ) is the master regulator of adipose cell differentiation and its functional activation is currently used as a therapeutic approach for Diabetes Mellitus type 2. Howev...
متن کاملA polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer
JMJD2C is a candidate oncogene that encodes a histone lysine demethylase with the ability to demethylate the lysine 9 residue of histone H3 (H3K9). The expression levels of JMJD2C are associated with tumor development and clinical outcome. Here we identify JMJD2C as a new substrate for caspase-3. JMJD2C is cleaved by caspase-3 at DEVD396G motif and then loses its demethylase activity. Additiona...
متن کاملNCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect
Herein, we investigated therapeutic potential of a novel histone lysine demethylase 1 (LSD1) inhibitor, NCL1, in prostate cancer. Hormone-sensitive prostate cancer cells, (LNCaP) and castration resistant cancer cells (PC3 and PCai1) were treated with NCL1, and LSD1 expression and cell viability were assessed. Prostate cancer cells showed strong LSD1 expression, and cell viability was decreased ...
متن کاملAWARD NUMBER: W81XWH-15-1-0236 TITLE: Phosphoproteomic Assessment of Therapeutic Kinases for Personalized Therapy in Castration-Resistant Prostate Cancer PRINCIPAL INVESTIGATOR:
TITLE: Phosphoproteomic Assessment of Therapeutic Kinases for Personalized Therapy in Castration-Resistant Prostate Cancer PRINCIPAL INVESTIGATOR: Justin M. Drake CONTRACTING ORGANIZATION: Rutgers, The State University of New Jersey New Brunswick NJ 08903 REPORT DATE: October 2016 TYPE OF REPORT: Annual PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013